Syndax's Transplant Surprise: The Better Revuforj Works, the Bigger the 2027 Tailwind
Q3 revenue jumped 82%, but the real signal is NPM1 patients going to transplant at 40% — roughly four times the trial rate — and coming back for years.
SNDX · Earnings Call · 2026-11-02
Syndax entered 2026 with a simple debate: could Revuforj keep growing after a second-quarter wobble in new patient starts? The third quarter answered yes, but in a way that complicates the model. Total revenue reached $83.3 million, up 82% year over year. Revuforj net revenue was $60.7 million, up 90% year over year and 11% sequentially. Niktimvo net sales were $67 million, up 47%. More important, the demand mix is rotating toward relapsed/refractory NPM1, where claims data now show Revuforj taking the majority of new menin-inhibitor starts across age groups.
That mix shift is not cosmetic. “about 50% of new Revuforj patients this quarter were NPM1 patients... our NPM1 business accounted for more than 35% of the $61 million in net revenue this quarter” — Steven Closter, Chief Commercial Officer · 2026-11-02. A quarter earlier, management had told investors NPM1 was roughly 30% of new starts and would “likely pretty quickly go to 50-50” — Steven Closter, Chief Commercial Officer · 2026-02-26. That prediction arrived faster than the revenue line implies, because NPM1 patients are older, more likely to be treated in the community, and — until this quarter — assumed to be less likely to proceed to transplant.
Q2's new-start decline was called an anomaly; in August, management insisted “we look at this quarter as an anomaly” — Steven Closter, Chief Commercial Officer · 2026-08-03. Q3 backed that up. New starts rose about 20% sequentially to roughly 300 patients, total prescriptions rose 13% to about 1,700, and the company added accounts at an 8% sequential clip. Yet revenue growth still lagged new-start growth. That gap is the story.
The transplant paradox
The freshest, most company-specific disclosure on the call was not the revenue print. It was the transplant rate. In the pivotal NPM1 trial, only about 11% of patients went to transplant after Revuforj. In commercial claims, the company now estimates about 40% of NPM1 patients are proceeding to transplant, with roughly half resuming therapy afterward. KMT2A is further along: about 50% go to transplant, and about 60% resume, up from about 50% last quarter. “50% of the patients who have KMT2A and gone to transplant, 60% of them are now getting maintenance... NPM1 ... now 40% with 50% of patients resuming with maintenance” — Michael Metzger, Chief Executive Officer · 2026-11-02.
This is the transplant rate becoming a growth variable rather than a clinical footnote. It also explains the near-term air pocket: patients pause Revuforj for two to five months around transplant, so a successful bridge to transplant temporarily removes revenue. The resume therapy cohort then returns for one to two years of maintenance, extending long duration and stacking revenue in 2027 and beyond. Management was explicit that the inflection is not immediate.
So yes, I think 2027 is where you'll see the greatest impact. We have started to see some of that, but we'll start to see more as it stacks in '27.
This is a classic biotech launch trap: the better the drug works, the worse the near-term revenue optics, because success routes patients into a temporary treatment holiday. The market may read the Q3 revenue growth versus new-start growth as softness; the company is arguing it is the leading edge of post transplant setting expansion. The stock, at a $1.17 billion market cap, is essentially being asked to underwrite that duration extension before it shows up cleanly in the P&L.
Niktimvo is the quiet compounder; the pipeline is the option
Niktimvo remains a steady second leg. Third-quarter net sales were $67 million, up 47% year over year and 12% sequentially, with more than 300 new patients and about 6,350 infusions. Collaboration revenue to Syndax was $22.6 million, and the product is annualizing above $260 million. Management again compared the trajectory with Rezurock, which reached $500 million in annual U.S. net sales within four years in the same indication. The margin contribution was 34% this quarter, flattered by a one-time adjustment; the go-forward guide is low-to-mid 30%, up from the earlier 25% to 30% range.
The near-term catalyst slipped, though. The Phase 2 frontline chronic GVHD trial of axatilimab plus ruxolitinib is now expected to report in the first quarter of 2027, not later this year, so the company can present a mature dataset including event-free survival. The Phase 3 trial with corticosteroids is expected in early 2028. That is not a bust, but it pushes the next leg of the Niktimvo story out by a quarter or two.
Earlier-stage pipeline assets are also moving. SNDX-4321, a mutant-selective EGFR inhibitor for non-small cell lung cancer, has an IND targeted by the end of 2026. SNDX-62122, a next-generation menin inhibitor for myelofibrosis, is expected to enter the clinic next year, supported by a revumenib proof-of-principle trial in myelofibrosis starting in the fourth quarter of 2026. These are high unmet need shots, but they are not near-term revenue.
Frontline is the real prize — and the real risk
Revuforj's $2 billion-plus U.S. peak revenue ambition assumes frontline AML. ASH in December will feature front-line combination data from BEAT AML, SAVE, and the intensive-chemotherapy study, which management says will support the EVOLVE-2 and REVEAL pivotal trials. Analysts pressed on enrollment timelines; management declined to guide. Competition from J&J and Sumitomo may also show registration-enabling data at ASH. The CEO downplayed the threat: “we have not seen data obviously yet... our view on competition is that it's unlikely to be differentiated” — Michael Metzger, Chief Executive Officer · 2026-11-02. That may prove right, but the stock is not paying for "unlikely"; it is paying for first-to-frontline execution. The absence of enrollment guidance is a small yellow flag.
The balance sheet and valuation
Using the last filed fundamentals, total revenue was $73 million in Q2 before stepping to $83.3 million in Q3. Operating income was -$40 million and net income -$49 million in Q2, so the company is still burning cash even as the top line scales. The reported cash position improved to $551 million at Q3, but the last balance sheet showed effective net cash of $436 million, down from a peak of $876 million in 2023. The liabilities-to-assets ratio was 97.9%, up sharply over the past year — largely the financing structure behind the royalty monetization rather than a near-term solvency event, but it means the equity is a call option on Revuforj's duration and frontline data. At roughly 7.7x price-to-revenue, the market is paying for growth but not yet for the full frontline option.
Bottom line: Q3 was not a clean beat — it was a reveal. Revuforj's NPM1 transplant rate came in roughly four times the trial experience, creating a near-term revenue pause and a 2027 tailwind. If management is right, current revenue growth understates the durability of the franchise. If it is wrong, the market will refocus on cash burn and the frontline timeline. The next catalyst is ASH, where the data will either validate the "menin inhibitor of choice" claim or expose how crowded the frontline race has become.